Apogee Therapeutics Inc. emerged from stealth with $169 million in financing and a pipeline of four preclinical antibody development programs that take aim at major immunological and inflammatory disorders.

Research conducted at Inflection Biosciences Ltd. and affiliated organizations has led to the discovery of a novel pan-PIM kinase inhibitor, IBL-101, as a potential therapeutic candidate for autoimmune disease, including psoriasis.

Investigators at the University of Bristol and Biognos AB have identified a structural feature that distinguished the deadly coronavirus strains from harmless, common cold-causing variants. The findings, which were published in the Nov. 23, 2022, issue of Science Advances, could form the basis of universal COVID antivirals, putting an end to the endless race to deal with new variants that has so far been a necessity.

Mast cells (MCs) are tissue-resident immune cells and are responsible for allergic and inflammatory processes. One potential approach for targeting MCs is to engage inhibitory receptors that can silence MC activation, such as sialic acid-binding immunoglobulin-like lectins (siglecs). Siglec-6 is an inhibitory receptor expressed on human MCs and represents an attractive therapeutic target for this purpose. Siglec-6 engagement with a monoclonal antibody (MAb) was recently shown to inhibit MC activation in vitro.

Does cancer cause autoimmune disease or is it the other way around? In looking at the question of which comes first, the chicken or the egg, researchers at the Garvan Institute of Medical Research in Australia found that a genetic mutation that alters immune cells in leukemia is behind certain autoimmune disorders.

A combination of radiation therapy and CD47 blockade induced an abscopal effect in animal studies even in animals that lacked T cells, researchers reported in the Nov. 21, 2022, online issue of Nature Cancer.

Emergex Vaccines Holding Ltd. has generated a chikungunya virus (CHIKV) ligandome, the first major milestone in the development of the company's CD8+ T-cell CHIKV adaptive vaccine candidate. Using an immunoproteomics approach, naturally presented MHC Class I-restricted peptides on the surface of a human leukocyte antigen (HLA)-typed cell line infected with CHIKV virus were extracted and identified.

Researchers from King's College London and UCB Pharma Inc. recently reported preclinical data on the effects of an anti-mouse neonatal Fc receptor (FcRn) antibody, UCB-4470, on circulating antiphospholipid (aPL) and aPL-induced thrombus formation in mice.